Direct Transcranial Electrical Stimulation in Tobacco Addiction (tDCS)
NCT ID: NCT04209153
Last Updated: 2025-09-12
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
100 participants
OBSERVATIONAL
2021-11-29
2028-05-29
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Transcranial Direct Current Stimulation - Tobacco Use Disorder
NCT03691805
Using Non-invasive Brain Stimulation (tDCS) With Varenicline for Treating Tobacco Dependence
NCT03841292
tDCS Plus Varenicline for Smoking Cessation
NCT06798324
Transcranial Direct Current Stimulation in a Smoking Cessation Trial
NCT01710410
The Use of TDCS for Vaping Reduction
NCT06885606
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Transcranial Direct Current Stimulation
tDCS sessions (with Direct Transcranial Electrical Stimulation (tDCS) device - Neuroelectrics
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Nicotine dependent subjects according to the Fagerström test (score ≥5)
* Subjects consuming daily tobacco.
* Subjects understanding and reading French and able to express themselves in this language.
* Signed informed consent to participate indicating that the subject has understood the purpose and the procedures required by the study and agrees to participate in the study and to comply with the requirements and limitations of this study
* Affiliation to the French social security scheme or beneficiary of such a scheme.
* No other method to decrease or stop smoking at the same time as the study.
Exclusion Criteria
* Pregnant or lactating woman
* Patient under AME
* Subject being in the exclusion period of another study or provided for by the "National Volunteer File".
* Subjects with intracranial hypertension
* Subject unlikely to cooperate with the study and / or weak cooperation anticipated by the investigator.
* Treatment with buproprion or varenicline in progress
* Episode or family history of epilepsy, convulsion.
* Disease causing damage to the brain (aneurysm, tumor, ...).
* Cochlear or ocular implant.
* Stimulator or cardiac defibrillator.
* Presence of metal in the skull (clip on aneurysm, prosthesis, ...).
* Eczema on the scalp.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
URC-CIC Paris Descartes Necker Cochin
OTHER
Assistance Publique - Hôpitaux de Paris
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Psychiatrie Adultes Et Addictologie
Paris, IDF, France
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Florence THIBAUT
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2019-A01946-51
Identifier Type: OTHER
Identifier Source: secondary_id
APHP190731
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.